Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.
Prostate Cancer
DRUG: Tesetaxel
Progression-free survival, 6 months from the start of treatment
Response rate (RECIST 1.1) among patients with measurable disease, 6 months from the start of treatment|Duration of response among patients with measurable disease, 12 months from the start of treatment|Durable response among patients with measurable disease, 12 months from the start of treatment|Overall survival, 3 years following enrollment of the last subject|Disease-control rate, 6 months from the start of treatment|PSA response rate, Week 12|Progression-free survival, 12 months from the start of treatment|No. (percentage) of subjects with adverse events, Through 30 days after the last dose of tesetaxel
Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.